Zydus Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Zydus Lifesciences has a total shareholder equity of ₹209.4B and total debt of ₹1.9B, which brings its debt-to-equity ratio to 0.9%. Its total assets and total liabilities are ₹258.8B and ₹49.4B respectively. Zydus Lifesciences's EBIT is ₹42.5B making its interest coverage ratio -616.6. It has cash and short-term investments of ₹15.2B.
Key information
0.9%
Debt to equity ratio
₹1.92b
Debt
| Interest coverage ratio | -616.6x |
| Cash | ₹15.20b |
| Equity | ₹209.41b |
| Total liabilities | ₹49.39b |
| Total assets | ₹258.79b |
Recent financial health updates
Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27
We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Jul 07Recent updates
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Aug 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 25Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50
Jul 10Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Jul 07Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 23Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50
Jun 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50
May 26Financial Position Analysis
Short Term Liabilities: ZYDUSLIFE's short term assets (₹99.3B) exceed its short term liabilities (₹43.6B).
Long Term Liabilities: ZYDUSLIFE's short term assets (₹99.3B) exceed its long term liabilities (₹5.8B).
Debt to Equity History and Analysis
Debt Level: ZYDUSLIFE has more cash than its total debt.
Reducing Debt: ZYDUSLIFE's debt to equity ratio has reduced from 57.7% to 0.9% over the past 5 years.
Debt Coverage: ZYDUSLIFE's debt is well covered by operating cash flow (1965.9%).
Interest Coverage: ZYDUSLIFE earns more interest than it pays, so coverage of interest payments is not a concern.